Frontiers in medicine · 2026
Placenta-pulmonary coupling-guided multimodal AI for fetal lung maturity staging and individualized glucocorticoid therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Bin, Ran Jie, Pan Ting, Yan Feilei, Yue Zhicheng, Yao Yanwu, Li Yongxin, Nie Fang
Аннотация
BACKGROUND AND AIM: Deep learning has improved medical image analysis but often produces opaque decisions and correlation-driven predictions that may diverge from clinical reasoning. We hypothesize that a physiology-informed hybrid framework, which explicitly models placenta-pulmonary interactions and integrates multimodal data, could provide interpretable and reliable guidance for assessing fetal lung maturity (FLM) and optimizing antenatal glucocorticoids (GCs).
MATERIALS AND METHODS: In a prospective cohort study involving 320 pregnancies-including 160 with hypertensive disorders of pregnancy (HDP)-each with weekly acquisitions from 28 to 36 weeks, we combined 2D/3D ultrasound, shear-wave elastography, Doppler, and maternal plasma metabolomics. A biophysical placenta-pulmonary coupling model used the umbilical artery pulsatility index (PI) and a metabolomic hypoxia-steroid score to represent placental reserve, while backscatter integrals and elastography were used to characterize fetal lung properties. Constrained by this model, a dual-branch network was developed: (i) a cross-modal attention Transformer with self-supervised contrastive learning to generate unsupervised FLM stages from fused representations and (ii) a spatiotemporal convolution-LSTM network to predict individualized GC dosing and the optimal administration window. A composite loss penalized both projected respiratory distress syndrome (RDS) risk and the biomarker-derived neurotoxicity index.
RESULTS: The cross-modal representations clustered into four distinct maturity stages matching biochemical benchmarks, with an inter-stage silhouette score of 0.72. A downstream classifier achieved 92.3% accuracy in discriminating early from late maturity. The dosing branch predicted the GC dose within ±0.5 mg of clinically prescribed regimens and reduced projected RDS risk by 27% compared to standard dosing, while maintaining the biomarker-derived neurotoxicity index below the prespecified threshold.
CONCLUSION: A mechanism-guided, multimodal AI framework constrained by placenta-pulmonary physiology transforms imaging features into traceable decision pathways that align with clinical cognition. This interpretable framework may enable non-invasive FLM staging and individualized GC therapy, providing hypothesis-generating decision support that warrants external validation and prospective trials.
MATERIALS AND METHODS: In a prospective cohort study involving 320 pregnancies-including 160 with hypertensive disorders of pregnancy (HDP)-each with weekly acquisitions from 28 to 36 weeks, we combined 2D/3D ultrasound, shear-wave elastography, Doppler, and maternal plasma metabolomics. A biophysical placenta-pulmonary coupling model used the umbilical artery pulsatility index (PI) and a metabolomic hypoxia-steroid score to represent placental reserve, while backscatter integrals and elastography were used to characterize fetal lung properties. Constrained by this model, a dual-branch network was developed: (i) a cross-modal attention Transformer with self-supervised contrastive learning to generate unsupervised FLM stages from fused representations and (ii) a spatiotemporal convolution-LSTM network to predict individualized GC dosing and the optimal administration window. A composite loss penalized both projected respiratory distress syndrome (RDS) risk and the biomarker-derived neurotoxicity index.
RESULTS: The cross-modal representations clustered into four distinct maturity stages matching biochemical benchmarks, with an inter-stage silhouette score of 0.72. A downstream classifier achieved 92.3% accuracy in discriminating early from late maturity. The dosing branch predicted the GC dose within ±0.5 mg of clinically prescribed regimens and reduced projected RDS risk by 27% compared to standard dosing, while maintaining the biomarker-derived neurotoxicity index below the prespecified threshold.
CONCLUSION: A mechanism-guided, multimodal AI framework constrained by placenta-pulmonary physiology transforms imaging features into traceable decision pathways that align with clinical cognition. This interpretable framework may enable non-invasive FLM staging and individualized GC therapy, providing hypothesis-generating decision support that warrants external validation and prospective trials.